Vascular Surgery · Clinical Reference
Antiplatelet Therapy in Peripheral Arterial Disease
Evidence-based · Case-oriented · Vascular surgery clinical reference
Sources: ESVS 2023/2024 · ACC/AHA 2024 · CAPRIE · COMPASS · VOYAGER PAD · CASPAR · Dutch BOA · CASTLE
Sources: ESVS 2023/2024 · ACC/AHA 2024 · CAPRIE · COMPASS · VOYAGER PAD · CASPAR · Dutch BOA · CASTLE
§ 01
Overview & Pharmacology of Antiplatelets
Aspirin · Clopidogrel · Cilostazol
Mechanism-to-Clinical Correlation
Mechanism-to-Clinical Correlation
Scope Note — Other Antiplatelet Classes & Why This Article Focuses on Three Agents
Several antiplatelet classes exist beyond aspirin, clopidogrel, and cilostazol. These include more potent oral P2Y12 inhibitors such as ticagrelor and prasugrel, intravenous P2Y12 inhibition with cangrelor, GP IIb/IIIa inhibitors such as abciximab, eptifibatide, and tirofiban, phosphodiesterase-based drugs such as dipyridamole, and PAR-1 inhibition with vorapaxar.
| Other Antiplatelet Type | Examples | Why Not the Main Focus Here? |
|---|---|---|
| Potent oral P2Y12 inhibitors | Ticagrelor, prasugrel | Important in coronary practice, but not the routine backbone of PAD therapy. PAD-specific guideline use is narrower than aspirin or clopidogrel. |
| Intravenous P2Y12 inhibition | Cangrelor | Mainly peri-procedural/coronary use; not a chronic PAD medical-therapy drug. |
| GP IIb/IIIa inhibitors | Abciximab, eptifibatide, tirofiban | Potent short-term intravenous agents for selected acute catheter-based scenarios, not long-term PAD management. |
| Dipyridamole-based therapy | Dipyridamole ± aspirin | More commonly discussed in stroke prevention and selected access-patency literature; limited routine PAD role. |
| PAR-1 inhibition | Vorapaxar | Mechanistically relevant, but bleeding concerns and limited practical uptake keep it outside routine vascular-surgery protocols. |
Article Rationale This reference therefore focuses on aspirin, clopidogrel, and cilostazol because they are the agents most commonly encountered in vascular surgical decision-making: aspirin and clopidogrel form the core of cardiovascular and limb-event prevention, while cilostazol uniquely adds claudication and anti-restenosis relevance. Anticoagulation and dual-pathway inhibition are discussed separately because they are treatment strategies rather than pure antiplatelet classes.
Platelet Activation Cascade & Drug Targets
Aspirin (ASA)
COX-1 Inhibitor · Salicylate
PAD Dose75–100 mg once daily
Onset1–2 h (immediate effect)
DurationIrreversible · 7–10 days
MetabolismHydrolysis to salicylate
MonitoringRenal function · GI symptoms
Key SEGI ulceration · Bleeding
EvidenceCAPRIE, COMPASS
CAPRIE: Clopidogrel superior to aspirin in PAD subgroup (RRR 23.8% for PAD specifically). Aspirin remains first-line when clopidogrel unavailable or not tolerated. Higher doses (325 mg) offer no additional benefit and increase GI risk.
Clopidogrel
P2Y₁₂ Inhibitor · Thienopyridine Prodrug
PAD Dose75 mg once daily
Loading Dose300 mg (acute) or 600 mg
DurationIrreversible · 5–7 days
MetabolismProdrug → CYP2C19 activation
Resistance2–21% poor metabolisers
Key SEBleeding · TTP (rare)
EvidenceCAPRIE, CASPAR, ESVS 2023
CAPRIE (1996): Clopidogrel vs aspirin — 8.7% RRR in composite MACE. In PAD subgroup: 23.8% RRR — markedly superior. Preferred over aspirin as monotherapy per ESVS 2023 (Class IIa) and ACC/AHA 2024.
Cilostazol
PDE3 Inhibitor · Antiplatelet + Vasodilator
PAD Dose100 mg twice daily
Reduced Dose50 mg BD with CYP3A4/2C19 inhibitors or intolerance
DurationReversible · 24–48 h washout
IC Benefit↑MWD up to 50%; ↑QoL
Patency↓Restenosis post-EVT
Key CI⚠️ Heart failure (any grade)
EvidenceCASTLE, Megaly 2019, Chang 2025
Renal caution: follow local formulary. UK/EU SmPC contraindicates cilostazol when CrCl ≤25 mL/min; US labeling does not require renal dose adjustment but dialysis patients were not studied.
CASTLE (2008): Long-term safety confirmed — no increase in cardiac events vs placebo in non-HF patients. Additional mechanisms: vasodilation via vascular smooth muscle + ↓TG + ↑HDL (metabolic benefit). Approved in EU for IC management.
Cilostazol Absolute Contraindication
Heart failure of any grade is an absolute contraindication to cilostazol. This applies regardless of LVEF. All PDE3 inhibitors are associated with increased mortality in HF (FDA black box warning). Screen all patients for cardiac symptoms before prescribing. Do not assume preserved-EF HF is safe — it is not.
CYP2C19 Polymorphism — Clopidogrel Resistance
Up to 21% of patients (higher in Asian populations) are CYP2C19 poor metabolisers, rendering clopidogrel largely inactive. Clinically relevant in high-stakes scenarios (post-EVT, post-stenting). Testing not routine in PAD but consider in patients with recurrent thrombotic events on clopidogrel. Ticagrelor (reversible P2Y₁₂) is an alternative but is not specifically licensed for PAD and has limited ESVS evidence.
Mechanism Comparison Table
Mechanism-to-clinical correlation
Aspirin vs Clopidogrel vs Cilostazol
A compact clinical matrix comparing mechanism, reversibility, peri-procedural handling, and PAD-specific utility.
01Target
COX-1
P2Y₁₂ receptor
PDE3 enzyme
02Mechanism
↓TXA₂ synthesis
↓ADP-mediated activation; ↓cAMP fall
↑cAMP → ↓activation + vasodilation
03Reversibility
Irreversible — platelet lifespan
Irreversible — platelet lifespan
Reversible — 24–48 h
04Pre-op stop time
5–7 days, only if required
5 days
2–3 days
05Loading dose
300 mg in acute setting
300–600 mg
Not applicable
06Primary PAD indication
Cardiovascular risk reduction
Cardiovascular risk reduction — preferred
Intermittent claudication + patency support
07Heart failure use
Allowed
Allowed
Contraindicated
08Walking distance
No direct improvement
No significant direct effect
↑MWD 40–50% vs placebo
09Restenosis effect
Modest
Moderate
Significant after EVT
10Key evidence
CAPRIE · COMPASS
CAPRIE · CASPAR
CASTLE · Megaly 2019
§ 02
Antiplatelets in Best Medical Therapy
PAD · Dialysis AVF · Aortic Aneurysms
ESVS 2023/2024 · ACC/AHA 2024
ESVS 2023/2024 · ACC/AHA 2024
🩺 Clinical Vignette — Best Medical Therapy
A 68-year-old man with ABI 0.62, bilateral calf claudication at 150 metres, known ischaemic heart disease (PCI with DES 18 months ago), type 2 diabetes, and a 4.1 cm infrarenal AAA on surveillance. He is on aspirin 75 mg + ticagrelor 90 mg BD (for cardiac indication). No heart failure. eGFR 52 mL/min.
❓ What antiplatelet regimen is optimal? Can you add cilostazol? What about the AAA?
2.1 — Peripheral Arterial Disease (Stable & Symptomatic)
Asymptomatic PAD / Low ABI
Single antiplatelet therapy is reasonable/may be considered for cardiovascular risk reduction after individual bleeding-risk assessment. Evidence is stronger in symptomatic PAD. Aspirin or clopidogrel may be used; clopidogrel is often favoured when antiplatelet therapy is selected, based on CAPRIE PAD subgroup data. CAPRIE 1996 ACC/AHA 2024 ESVS 2024 IC Guidelines
Note: In truly asymptomatic PAD (no symptoms, incidental low ABI), avoid presenting APT as mandatory. Balance systemic atherosclerotic risk against bleeding risk.
Intermittent Claudication
Single APT (Class I): Clopidogrel preferred. ESVS 2023
Cilostazol (Class I for IC): 100 mg BD — improves maximal walking distance and pain-free walking distance vs placebo. CASTLE 2008 ESVS 2024 IC
Cilostazol adds to antiplatelet therapy rather than replacing it — use alongside single APT in IC.
Dual Pathway Inhibition (DPI) in Stable PAD — COMPASS Regimen
COMPASS (2018): Rivaroxaban 2.5 mg BD + Aspirin 100 mg vs aspirin alone in stable PAD/CAD. Anand et al. Lancet 2018
- MACE reduction: 21% relative risk reduction (CV death, MI, stroke)
- MALE reduction: 46% relative risk reduction (ALI, major amputation)
- Major bleeding: ↑ from 1.9% → 3.1% — but no increase in fatal or intracranial bleeding
- NNT (5 years) ≈ 17 for MACE; NNH ≈ 84 for major bleeding
ESVS 2023 Recommendation DPI (rivaroxaban 2.5 mg BD + aspirin 100 mg) should be considered for stable symptomatic PAD patients at high ischaemic risk and low bleeding risk. Class IIa, Level B.
2.2 — Dialysis Arteriovenous Fistula (AVF)
Antiplatelet Therapy & AVF Patency
Haemodialysis AVF patency is an important vascular surgical domain. APT evidence is more limited than in PAD proper.
| Scenario | Regimen | Evidence Level | Comment |
|---|---|---|---|
| Native AVF — new creation | Clopidogrel 75 mg OD up to 6 months may be considered; aspirin if clopidogrel contraindicated | Moderate / cautious | May reduce early thrombosis, but does not reliably improve dialysis suitability or maturation failure |
| AVG (prosthetic graft) | Single APT individualized; avoid routine DAPT | Low–Moderate | Higher thrombosis risk, but renal bleeding risk is substantial; surveillance and access technique remain decisive |
| Post-AVF thrombectomy | Single APT ± AC per indication | Low | No strong RCT data for DAPT post-declot; anticoagulation if hypercoagulable state |
| AF + AVF | DOAC monotherapy preferred | Moderate (ACC/AHA) | Avoid DAPT + anticoagulant triple therapy in renal patients — very high bleeding risk |
Renal Impairment Caution eGFR <30 significantly affects DOAC dosing and pharmacokinetics. Agent choice and dose must follow local renal/haematology policy; apixaban is commonly favoured in advanced CKD, but dialysis evidence remains limited. Avoid casual DOAC + DAPT stacking in renal patients.
2.3 — Abdominal Aortic Aneurysm (AAA) — Special Focus
Key Conceptual Point Antiplatelet therapy in AAA is given for cardiovascular risk reduction (MI, stroke prevention) — not primarily to slow aneurysm growth or prevent rupture. This distinction is critical. The aneurysm itself is managed by surveillance and timely repair based on size/growth thresholds.
ESVS 2024 AAA Guidelines — Antiplatelet Recommendations
| Recommendation | Class | Level | Reference |
|---|---|---|---|
| Single APT (aspirin or clopidogrel) as part of cardiovascular risk reduction in AAA patients with atherosclerotic risk | Class I | B | ESVS 2024 AAA, CAPRIE |
| Post-EVAR: single antiplatelet therapy long-term | Class I | C | ESVS 2024 AAA |
| Post-EVAR + AF: full-dose anticoagulation for AF; additional APT only if clearly indicated and time-limited | Class IIa | C | ESVS 2024 AAA / antithrombotic guidance |
| Post-F/B-EVAR (fenestrated/branched): early DAPT may be considered to support target-vessel patency | Class IIb | C | ESVS 2024 AAA; Nana et al. EJVES 2025 |
| APT to slow AAA growth or prevent rupture — not recommended as aneurysm-specific therapy | No routine role | B/C | ESVS 2024 AAA; observational literature |
⚗️ AAA Growth & Antiplatelet Therapy
Erdem Yaman & Poyraz (2024): Examined APT/anticoagulation in AAA growth and clinical outcomes. Anatol J Cardiol 2024
- Antiplatelet therapy: observational signals are inconsistent; evidence is not robust enough to recommend APT specifically for growth reduction
- Anticoagulation: some observational data suggest effects on intraluminal thrombus/expansion, but this is hypothesis-generating only; do not anticoagulate solely to slow AAA growth
- Statins: More consistent evidence for growth attenuation but not yet standard therapy solely for this purpose
- Doxycycline (MMP inhibitor): Early RCT data — no proven benefit in adequately powered trials
💥 AAA Rupture Risk & Antiplatelets
No strong evidence that antiplatelet therapy directly reduces rupture risk, and no convincing evidence that it increases rupture risk in non-ruptured AAA.
- Rupture risk is primarily driven by aneurysm diameter, growth rate, symptoms, sex, smoking, and morphology — not reliably modified by APT
- Large ILT burden may influence wall biology and biomechanics — APT effects on ILT have not translated into proven clinical rupture prevention
- APT does not modify threshold for surgical repair (5.5 cm men, 5.0 cm women per ESVS 2024)
- For ruptured AAA (rAAA): Continue existing APT — emergent repair takes priority; discuss with anaesthesia re. haemostasis
Post-EVAR & Complex Aneurysm (F/B-EVAR) — Antiplatelet Protocol
Standard EVAR: Single APT lifelong (aspirin or clopidogrel) + high-intensity statin + BP control. ESVS 2024 AAA
Fenestrated/Branched EVAR (F/B-EVAR): Nana et al. (2025) — role of APT in complex aortic aneurysms managed with F/B-EVAR: EJVES 2025
- DAPT (aspirin + clopidogrel) may be considered early post-procedure to support target-vessel patency, especially with multiple renal/visceral stents; evidence remains observational/low-level
- Typical practice: 3–6 months DAPT in selected low-bleeding-risk patients, then revert to single APT lifelong
- Monitor for access vessel complications; endoleak surveillance unchanged
§ 03
Perioperative Management — When to Stop & When to Start
Pre-revascularization Workup
ESVS 2023 Antithrombotic Guidelines · ACC/AHA 2024
ESVS 2023 Antithrombotic Guidelines · ACC/AHA 2024
🩺 Clinical Vignette — Perioperative Dilemma
A 74-year-old woman with critical limb-threatening ischaemia (Rutherford 5, forefoot ulcer) on aspirin 75 mg + clopidogrel 75 mg (for prior carotid endarterectomy 8 months ago). She requires an urgent femoro-popliteal bypass. Haemoglobin 10.8 g/dL. She has no coronary stents.
❓ Do you stop the DAPT? If so, which drug and when? Can she go to theatre on aspirin alone?
3.1 — Preoperative Assessment Framework
Risk Stratification — Thromboembolic Risk
- HIGH risk (do NOT stop without cardiology input):
- Bare metal coronary stent <4–6 weeks
- Drug-eluting coronary stent <6–12 months
- Recent ischaemic stroke <3 months (on DAPT)
- Recent ACS <3 months
- MODERATE risk (case-by-case):
- Prior CEA or carotid stenting >6 months ago
- Prior peripheral revascularisation on single APT
- Stable ischaemic heart disease, no recent stent
- LOW risk:
- Primary prevention APT
- Stable PAD, no recent events/procedures
Risk Stratification — Surgical Bleeding Risk
- HIGH bleeding risk — stop APT where possible:
- Neuraxial anaesthesia (epidural/spinal)
- Retroperitoneal surgery (open AAA repair)
- Complex hepatic/pancreatic surgery
- MODERATE:
- Open infrainguinal bypass (most vascular cases)
- Major amputations
- Open aorto-iliac work
- LOW — continue APT in most cases:
- Most endovascular procedures (angioplasty, stenting)
- Carotid endarterectomy (aspirin continued)
- Femoral endarterectomy
3.2 — When to Stop: Drug-Specific Guidance
Aspirin — Stopping Protocol
Continue
Endovascular
Most EVT procedures — aspirin should continue. Do not stop.
Continue
CEA
Aspirin continues through CEA — reduces stroke risk. ESVS Class I.
5–7 Days
Open Surgery (High Bleeding Risk)
If bleeding consequence is critical and after senior/anaesthetic decision. Restart ASAP post-op.
24–48 h
Restart
When surgical haemostasis is confirmed. Earlier for endovascular.
ESVS 2023 Antithrombotic — Aspirin is usually continued peri-operatively in vascular surgery unless bleeding consequences clearly outweigh thrombotic benefit.
Clopidogrel — Stopping Protocol
5 Days
Stop
For open vascular surgery. Allows new platelets to restore haemostasis.
Days 3–5
Washout
Residual platelet inhibition present. High-risk operations should wait full 5 days.
Continue
Endovascular (simple)
Angioplasty, femoral access — may continue clopidogrel. Case-by-case for stenting.
24–48 h
Restart
Post-open surgery when haemostasis confirmed. Day 1 post-EVT in most cases.
Coronary Stent — Never Stop Without Cardiology Advice
Drug-eluting stent <6–12 months or recent ACS: stopping P2Y₁₂ risks catastrophic in-stent thrombosis. Always discuss with cardiology. If surgery is urgent/emergent, continue DAPT and plan with haematology/anaesthesia. Bridging with GPIIb/IIIa inhibitors is controversial and not routinely recommended.
Cilostazol — Stopping Protocol
2–3 Days
Stop
Reversible mechanism — shorter washout than irreversible agents.
Day 1–2
Effect wanes
PDE3 inhibition reversible. Platelet function largely restored within 24–48 h.
24–48 h
Restart post-op
Can restart early post-EVT. Delay if open surgery until haemostasis confirmed.
Ongoing
Maintenance
Continue long-term for IC benefit. Review HF status at each review.
3.3 — Neuraxial Anaesthesia & Regional Blocks
| Drug | Stop Before Spinal/Epidural | Restart After Catheter Removal | Notes |
|---|---|---|---|
| Aspirin | No restriction for low-dose aspirin alone | Immediately | ASRA/ESRA: low-dose aspirin alone is generally not a contraindication to neuraxial techniques |
| Clopidogrel | 5–7 days before; many neuraxial protocols use 7 days | Usually ≥6 h after catheter removal | Strict — spinal haematoma risk if inadequate washout |
| Cilostazol | 36–48 h before | Usually ≥6 h after removal | Follow local anaesthesia policy; shorter washout than irreversible agents |
| Rivaroxaban | Separate vascular-dose from full-dose: low-dose may require ~24 h; therapeutic-dose commonly requires longer (often ~72 h) | Per anaesthesia protocol after catheter removal | Adjust for renal function, bleeding risk, and dose; do not use a single generic rivaroxaban rule |
| LMWH | Prophylactic: usually ≥12 h; therapeutic: usually ≥24 h | Per anaesthesia protocol | Therapeutic dosing and renal impairment require stricter timing |
§ 4A
Post-Revascularisation: Single APT vs DAPT
Open vs Endovascular · Evidence from CASPAR, VOYAGER PAD
ESVS 2023 · ACC/AHA 2024
ESVS 2023 · ACC/AHA 2024
🩺 Clinical Vignette — Post-Revascularisation
A 71-year-old man undergoes successful below-knee angioplasty and drug-eluting stent to the posterior tibial artery for a Rutherford 5 ischaemic ulcer. Pre-procedure he was on aspirin 75 mg only. No AF, no coronary stents. eGFR 68 mL/min. BP well-controlled.
❓ Single APT or DAPT post-EVT? For how long? Is rivaroxaban an option?
4A.1 — Post-Endovascular Therapy (EVT)
Decision Framework — Post-EVT Antiplatelet Therapy
| Scenario | Suggested Regimen | Duration | Evidence Position | Source |
|---|---|---|---|---|
| Below-knee EVT (infrapopliteal), especially stented/complex lesions | DAPT ASA + Clopidogrel is reasonable | 1–3 months; up to 6 months only in selected low-bleeding-risk cases | Reasonable / limited data | ACC/AHA 2024, ESVS 2023 |
| Above-knee EVT (iliac/fem-pop), simple angioplasty | Single APT or short DAPT if stented/complex | Usually 1 month DAPT if used, then single APT | Individualised | ESVS 2023, ACC/AHA 2024 |
| Drug-coated balloon / drug-eluting stent EVT | DAPT ASA + Clopidogrel is commonly used | 1–3 months, device/operator/bleeding-risk dependent | Reasonable / limited data | Device trials, ESVS 2023 |
| Post-EVT, high ischaemic/limb risk and acceptable bleeding risk | DPI Rivaroxaban 2.5 mg BD + ASA | Long-term if tolerated and no competing full-dose AC indication | Strong outcome evidence | VOYAGER PAD 2020, ACC/AHA 2024 |
| Post-EVT + AF | DOAC ± single APT | Individualised | IIa | ESVS 2023 |
VOYAGER PAD — Key Data for Post-EVT Practice Bonaca et al. NEJM 2020
Design: 6,564 patients with PAD post-revascularisation (75% EVT, 25% open surgery). Randomised to rivaroxaban 2.5 mg BD + aspirin 100 mg vs aspirin alone.
Primary outcome: Composite of ALI, major amputation, MI, ischaemic stroke, CV death
Result: 15% RRR (17.3% vs 19.9%; ARR 2.6%; NNT ≈ 38 over 3 years)
TIMI major bleeding: 2.65% vs 1.87% — significant increase, but no increase in fatal or intracranial bleeding
ISTH major bleeding: 5.94% vs 4.06%
⚡ VOYAGER establishes rivaroxaban 2.5 mg BD + aspirin as a strong evidence-based post-revascularisation option for PAD patients at high ischaemic/limb risk, provided bleeding risk is acceptable and there is no need for full-dose anticoagulation. This is Dual Pathway Inhibition (DPI), not traditional DAPT.
4A.2 — Post-Open Surgical Revascularisation
Open Bypass — Graft-Type Dependent Strategy
| Graft Type | Suggested Regimen | Duration | Evidence Position | Evidence |
|---|---|---|---|---|
| Autologous vein bypass (any level) | Single APT baseline; consider DPI if low bleeding risk; selected high-risk vein grafts may merit VKA | Lifelong SAPT/DPI; VKA individualized | Individualised | ESVS 2023, VOYAGER, Dutch BOA |
| Prosthetic graft — above knee | Single APT ASA or Clopidogrel | Lifelong | I | ESVS 2023 |
| Prosthetic graft — below knee | DAPT ASA + Clopidogrel | 3–6 months, then single APT | IIa | CASPAR, ESVS 2023 |
| Profundaplasty alone | Single APT | Lifelong | I | Expert consensus |
| Post-bypass, high ischaemic/limb risk and low bleeding risk | DPI Rivaroxaban 2.5 mg BD + ASA | Long-term if tolerated | Consider / guideline-supported | VOYAGER PAD surgical subset, ESVS 2023, ACC/AHA 2024 |
CASPAR Trial — Key Data Belch et al. J Vasc Surg 2010
Design: 851 patients undergoing infrainguinal bypass randomised to aspirin + clopidogrel vs aspirin + placebo (DAPT vs single APT post-open bypass)
Main result: No overall significant difference in graft occlusion, limb loss, or death between DAPT and single APT in the total population (HR 0.98 for DAPT).
Critical Subgroup Finding In the prosthetic graft below-knee subgroup: DAPT showed significant benefit — reduced occlusion and revascularisation events (HR 0.65, p=0.025). This is the basis for considering DAPT in below-knee prosthetic bypass. In vein graft recipients, DAPT offered no clear additional benefit over aspirin alone and increased bleeding burden.
Dutch BOA Study — Anticoagulation vs Aspirin Post-Bypass Lancet 2000
Design: 2,690 patients post-infrainguinal bypass randomised to oral anticoagulants (target INR 3.0–4.5) vs aspirin 80 mg.
Main result: No significant overall difference in graft occlusion or composite outcome between groups. Oral anticoagulation associated with significantly more bleeding.
Subgroup: Vein bypass patients — trend toward benefit with oral anticoagulation (non-significant overall). This finding influenced subsequent practice of considering anticoagulation in certain high-risk vein bypass patients.
⚡ Routine anticoagulation post-bypass is NOT recommended. Aspirin remains first-line. Anticoagulation is reserved for specific high-risk cases (hypercoagulable state, recurrent graft failure, selected vein bypass). If VKA is chosen for graft patency, use contemporary guideline targets rather than the older BOA trial intensity: INR 2.0–3.0, target 2.5.
§ 4B
Triple Antiplatelet Therapy
Aspirin + Clopidogrel + Cilostazol
Evidence, Rationale & Limitations
Evidence, Rationale & Limitations
Evidence Caveat Triple antiplatelet therapy (ASA + clopidogrel + cilostazol) has a limited and largely observational evidence base in PAD. There are no large, adequately powered RCTs specifically examining triple APT in peripheral arterial disease. The evidence below is drawn from post-EVT observational studies, PAD subgroup analyses, and extrapolation from cerebrovascular disease trials. Clinical use should be highly individualised.
Mechanistic Rationale for Triple APT
Each agent targets a distinct pathway in platelet activation — additive but non-overlapping inhibition:
- Aspirin → blocks TXA₂ (COX-1 pathway)
- Clopidogrel → blocks ADP signalling (P2Y₁₂)
- Cilostazol → raises cAMP via PDE3 inhibition + vasodilation
Gurbel et al. (2019): rationale for combining antiplatelet and anticoagulant mechanisms — thrombus has both platelet-rich and fibrin components. The “triple” concept extends this to target both the ADP and TXA₂ pathways plus PDE3-cAMP amplification. Gurbel et al. 2019
Where Triple APT May Be Used (Selected Cases)
- Post-complex infrapopliteal EVT with high restenosis risk (e.g. SFA/below-knee, long lesion, calcified)
- Post-EVT where DAPT is already established and cilostazol is added for IC benefit
- Recurrent in-stent restenosis with ongoing claudication
- Patients not eligible for DPI where restenosis risk, rather than systemic thrombosis risk, is the dominant concern
- Transitional period post-EVT: DAPT + cilostazol for 1–3 months, then reassess
Evidence for Triple APT & Cilostazol Combinations
| Study | Comparison | Finding | Relevance |
|---|---|---|---|
| Chang et al. 2025 Vasc Med | Cilostazol post-EVT vs no cilostazol | ↓Restenosis, ↓repeat angioplasty (TLR), improved primary patency | Supports cilostazol addition post-EVT in high-risk lesions |
| Megaly et al. 2019 Vasc Med | Cilostazol after EVT (meta-analysis) | Improved primary patency; reduced TLR; no significant bleeding signal | Meta-analysis: cilostazol beneficial post-EVT |
| Toyoda et al. 2014 Stroke 2014 | Cilostazol + aspirin vs DAPT (aspirin + clopidogrel) in cerebral artery disease | Cilostazol combination: ↓haemorrhagic events vs DAPT; similar efficacy | Suggests cilostazol may offer safer alternative to clopidogrel in dual-therapy context |
| ESVS 2023 | Triple APT guidance | No formal Class I recommendation; insufficient RCT data | Triple APT not standard — but not contraindicated in selected cases |
⚠️ Bleeding Risk with Triple APT
Yu et al. (2021): More antithrombotic agents → proportionally more bleeding complications. Each additional agent adds incremental risk. Yu et al. 2021
- Triple APT (ASA + clopidogrel + cilostazol) should be time-limited — typically 1–3 months maximum
- Review at each outpatient visit — step down to DAPT or single APT as soon as appropriate
- Baseline GI protection: prescribe PPI in all patients on dual or triple antiplatelet therapy
- Cilostazol does not inhibit COX-1 or P2Y₁₂ — its bleeding contribution is via cAMP-mediated platelet suppression but the absolute risk increment is modest
- Key exclusions: GI ulceration, recent bleeding, thrombocytopaenia (<100), active malignancy, age >80 with frailty
Prescribing Checklist Before Triple APT
✅ Before Prescribing Triple APT
- ☑ Confirmed indication for DAPT component
- ☑ Confirmed indication for cilostazol (IC or restenosis risk)
- ☑ No heart failure (any grade) — absolute CI for cilostazol
- ☑ Renal function and local formulary reviewed — avoid/contraindicated in severe renal impairment where applicable; 50 mg BD is mainly for CYP3A4/2C19 inhibitors or intolerance
- ☑ PPI co-prescribed when bleeding/GI risk is relevant — prefer pantoprazole when clopidogrel is used
- ☑ Patient counselled on bleeding risk and HF symptoms
- ☑ Planned duration specified (<3 months unless compelling reason)
- ☑ Stop plan documented (step-down protocol)
🚫 When NOT to Use Triple APT
- Heart failure (any grade or EF)
- Concurrent anticoagulation (triple therapy becomes quadruple)
- Recent major bleeding (<3 months)
- Active peptic ulcer disease
- Thrombocytopaenia <100 × 10⁹/L
- Severe hepatic impairment
- No clear indication for cilostazol component
- Patient unable to comply with monitoring
§ 4C
Cilostazol — Effect, Indications & Adding to DAPT
CASTLE · Megaly 2019 · Chang 2025
Step-by-step addition protocol
Step-by-step addition protocol
4C.1 — Unique Properties of Cilostazol
Antiplatelet + Vasodilatory Effects
- PDE3 inhibition → ↑cAMP in platelets → ↓activation and aggregation
- PDE3 in vascular smooth muscle → vasorelaxation → ↑arterial diameter → improved limb blood flow
- Anti-proliferative on vascular smooth muscle → ↓intimal hyperplasia → ↓restenosis
- Lipid effects: ↓TG, ↑HDL (modest)
- Walking distance: ↑Maximal walking distance 40–50% vs placebo in IC (Class I indication, ESVS 2024 IC Guidelines)
Post-EVT Patency — Megaly 2019 Meta-Analysis Vasc Med 2019
- Pooled analysis of cilostazol use post-EVT for PAD
- Primary patency: Significantly improved (OR 1.54)
- Target lesion revascularisation (TLR): Significantly reduced
- Limb salvage: No significant difference
- Bleeding: No significant increase vs control
- Several studies used cilostazol on top of background antiplatelet therapy, often including DAPT — supporting selected, time-limited use rather than routine triple APT for every post-EVT patient
4C.2 — How to Add Cilostazol to an Established DAPT Regimen
🔄 Step-by-Step Protocol: Adding Cilostazol to DAPT
1
CONFIRM INDICATION FOR CILOSTAZOL
Patient has IC limiting daily activity OR high restenosis risk post-EVT (complex below-knee lesion, in-stent restenosis, diffuse disease). Cilostazol should not be added without a specific indication.
2
EXCLUSION CHECK (MANDATORY)
- Heart failure (any grade, any EF) — ABSOLUTE CONTRAINDICATION → Do NOT proceed
- Unstable angina / decompensated cardiac disease
- Active bleeding / high bleeding risk
- Concurrent anticoagulation — reassess risk/benefit carefully before adding
- Check renal function and local formulary; review CYP3A4/2C19 inhibitors
- Review all drug interactions (e.g. CYP3A4 inhibitors: erythromycin, diltiazem, itraconazole → ↑cilostazol levels)
3
START DOSE & CO-PRESCRIBE PPI
Cilostazol 100 mg BD, taken 30 minutes before or 2 hours after meals. Use 50 mg BD with moderate/strong CYP3A4 or CYP2C19 inhibitors or if poorly tolerated. In severe renal impairment, follow local formulary: UK/EU SmPC contraindicates use when CrCl ≤25 mL/min, while US labeling does not require renal dose adjustment but dialysis patients were not studied. Co-prescribe GI protection when bleeding/GI risk is relevant; prefer pantoprazole rather than pantoprazole when clopidogrel is used. Warn patient about: headache (common, usually settles 2 weeks), palpitations, diarrhoea, dizziness.
4
SPECIFY DURATION & STEP-DOWN PLAN
For post-EVT restenosis prevention: typically 3–6 months, then review. For IC: ongoing if tolerated and beneficial, reviewing at each clinic. Set a review date in clinic letters. Step-down plan: after planned duration, stop clopidogrel first (if DAPT was post-EVT and interval elapsed), continue aspirin + cilostazol if IC benefit ongoing, or step to aspirin alone.
✓
MONITORING AT FOLLOW-UP
At 4–6 week review: assess for HF symptoms (dyspnoea, ankle oedema, orthopnoea), significant palpitations, bleeding. Check BP, HR. Reassess walking distance (six-minute walk or treadmill). If developing HF: stop cilostazol immediately. If no benefit at 3 months: discontinue.
Timing of Cilostazol Post-EVT
Cilostazol can be started after EVT once access-site haemostasis is confirmed and there is no immediate bleeding concern. Its effect is additive to existing antiplatelet therapy, so the indication and stop date should be explicit. Post-open surgery: wait until surgical haemostasis is established, commonly 24–48 h. Do NOT give intraoperatively.
4C.3 — Cilostazol vs Clopidogrel: Is Cilostazol an Alternative?
Toyoda et al. (2014) — Cilostazol-Based Combinations Stroke 2014
In the context of cerebrovascular disease (extrapolated with caution to PAD): cilostazol + aspirin was compared to DAPT (aspirin + clopidogrel). Cilostazol combination showed: fewer haemorrhagic complications, similar ischaemic event rates. This supports the concept that cilostazol + aspirin may be a safer alternative to traditional DAPT in patients at high bleeding risk — but this data is stroke-specific and should not be directly applied to peripheral vascular disease without caution. Toyoda et al. 2014
§ 4D
Anticoagulation: When, How & What Dose
Dual Pathway Inhibition · DOACs · Warfarin
COMPASS · VOYAGER · ESVS 2023
COMPASS · VOYAGER · ESVS 2023
🩺 Clinical Vignette — Anticoagulation Decision
A 66-year-old woman, 6 weeks post right femoro-popliteal bypass with PTFE for Rutherford 5 ischaemia. She has now been diagnosed with paroxysmal AF on a 14-day Holter monitor. She is currently on aspirin 75 mg + clopidogrel 75 mg (post-bypass DAPT). eGFR 55 mL/min. No prior bleeding history. CHA₂DS₂-VASc = 5.
❓ How do you integrate an anticoagulant? Stop DAPT? Which DOAC? What dose?
4D.1 — Indications to Add Anticoagulation
When to Add Anticoagulation in PAD / Post-Revascularisation
| Indication | Preferred Agent | Notes |
|---|---|---|
| Atrial fibrillation (AF) — CHA₂DS₂-VASc ≥1 (M) / ≥2 (F) | DOAC (apixaban/rivaroxaban) | AF is primary indication; PAD does not change DOAC selection. Minimise duration of concurrent APT. |
| Prior DVT / PE (VTE history) | DOAC (apixaban/rivaroxaban) | Standard VTE dosing. Consider if PAD is stable to reduce total antithrombotic burden |
| Mechanical prosthetic heart valve | Warfarin ONLY (INR 2.5–3.5) | DOACs are contraindicated with mechanical valves. Warfarin is mandatory. |
| Hypercoagulable state (antiphospholipid, factor V Leiden with events) | Warfarin (INR 2.5–3.5) or DOAC per specialist advice | Thrombophilia specialist input required. LMWH may be preferred in some. |
| High-risk post-EVT PAD (VOYAGER/COMPASS regimen) | Rivaroxaban 2.5 mg BD + Aspirin 100 mg | This is DPI, not anticoagulation per se — “vascular dose” rivaroxaban. Different from standard AC doses. |
| Recurrent bypass graft thrombosis | Warfarin (INR 3.0–4.5) or DOAC | Dutch BOA subgroup suggests benefit in vein bypass; high bleeding risk — individualise |
4D.2 — Dual Pathway Inhibition (DPI): The COMPASS/VOYAGER Regimen
What is DPI? (Rivaroxaban 2.5 mg BD + Aspirin 100 mg)
This is not standard anticoagulation. Rivaroxaban 2.5 mg BD is a subtherapeutic anticoagulant dose — it does not achieve therapeutic anticoagulation for AF or VTE treatment. It does, however, reduce thrombin generation at the platelet surface and in the thrombus environment, combined with platelet inhibition via aspirin. This dual mechanism (antiplatelet + subclinical anticoagulant) is referred to as Dual Pathway Inhibition. Jurk et al. 2022
COMPASS (STABLE PAD)
- 21% RRR MACE
- 46% RRR MALE
- NNT ≈ 17 (5y, MACE)
- ↑Major bleeding but no fatal/IC bleed
- Class IIa, Level B — ESVS 2023
VOYAGER (POST-REVASCULARISATION)
- 15% RRR composite (ALI, amputation, MI, stroke, CV death)
- 24% RRR ALI specifically
- NNT ≈ 38 (3y)
- ↑TIMI major bleed — no fatal bleed
- Class IIa — ESVS 2023
4D.3 — DOAC Dosing in PAD Patients
Anticoagulation Dosing Reference — PAD & Vascular Patients
Rivaroxaban (DPI/vascular dose)
2.5 mg twice daily + Aspirin 100 mg OD (COMPASS/VOYAGER)
Rivaroxaban (AF standard dose)
20 mg OD with evening meal (eGFR ≥50) · 15 mg OD (eGFR 15–49)
Apixaban (AF standard dose)
5 mg BD · Reduce to 2.5 mg BD if ≥2 of: age ≥80, weight ≤60 kg, Cr ≥133 μmol/L
Apixaban (VTE treatment)
10 mg BD × 7 days, then 5 mg BD (preferred in CKD — least renal clearance ~27%)
Dabigatran (AF)
150 mg BD · 110 mg BD if age ≥80, high bleed risk, or CrCl 30–50 · Avoid CrCl <30
Warfarin (standard)
Target INR 2.0–3.0 (most indications) · 2.5–3.5 (mechanical mitral valve) · 3.0–4.5 (recurrent bypass, Dutch BOA)
LMWH — Enoxaparin (bridging/prophylaxis)
Prophylactic: 40 mg SC OD · Therapeutic: 1 mg/kg BD or 1.5 mg/kg OD
4D.4 — Combining Anticoagulation with APT: Practical Protocol
How to Integrate AC into APT Regimen — Decision Framework
| Clinical Scenario | Recommended Regimen | Avoid | Duration |
|---|---|---|---|
| Stable PAD + AF | Full-dose DOAC monotherapy in most cases; add APT only for a clear, usually time-limited vascular/coronary indication | DAPT + anticoagulant (triple = very high bleeding risk) | Indefinite AF indication drives duration |
| Post-EVT + AF (new diagnosis) | Full-dose DOAC + single APT only if recent intervention risk justifies it; keep duration short, often 1 month and rarely up to 3 months | Continue DAPT + add full-dose DOAC (= triple therapy, maximum bleeding risk) | Transition to DOAC alone once limb/stent risk stabilises |
| Post-EVT + no AF (high ischaemic risk) | DPI: Rivaroxaban 2.5 mg BD + Aspirin 100 mg | Full-dose DOAC without specific indication (unnecessary bleeding risk) | Long-term (VOYAGER regimen) |
| Post-bypass + AF | Full-dose DOAC; add single APT only if graft/device risk justifies it | DAPT + DOAC | Individualise early and document stop date |
| Post-bypass + mechanical valve | Warfarin (INR 2.5–3.5) + aspirin | DOAC (CI with mechanical valve) | Lifelong warfarin |
| Triple antithrombotic required (AF + recent stent + PAD) | DOAC + aspirin + clopidogrel for minimum duration (<1 month), then step to DOAC + aspirin | Prolonged triple therapy; avoid >1 month unless exceptional circumstances | <1 month triple, then DOAC + single APT |
Triple Antithrombotic Therapy (DOAC/Warfarin + DAPT) — Maximum Bleeding Risk
DOAC or warfarin + aspirin + clopidogrel = triple therapy. This carries a 3–4× higher major bleeding risk compared to DOAC monotherapy. Yu et al. (2021) confirm proportional bleeding risk with each additional agent. This regimen should be used for the minimum possible duration and only when the ischaemic indication is overwhelming (e.g. AF + ACS + peripheral stent). Always set a clear stop date. Use GI protection when indicated, preferably pantoprazole if clopidogrel is used. Consider haematology or cardiology co-management. Yu et al. 2021
AF + PAD: Practical Decision
CHA₂DS₂-VASc ≥1 (M) / ≥2 (F): start DOAC. In PAD: apixaban/rivaroxaban preferred.
- If stable PAD on single APT → add DOAC, consider stopping APT after 3–6 months (DOAC monotherapy reduces MALE in AF trials)
- If post-EVT <6 months → DOAC + aspirin for initial period, then DOAC alone
- If post-open bypass on DAPT → stop clopidogrel early where possible; continue DOAC ± single APT according to graft/device risk
- HAS-BLED score: calculate in every patient before anticoagulation
CKD & Anticoagulation in PAD
- eGFR 30–50: All DOACs usable with dose adjustment. Apixaban preferred (least renal clearance).
- eGFR 15–29: Apixaban with monitoring (limited data; used in practice). Avoid dabigatran. Avoid rivaroxaban. Warfarin alternative.
- eGFR <15 / dialysis: Warfarin or apixaban (limited evidence). No DOAC is fully validated on dialysis.
- Cilostazol: follow local formulary in severe renal impairment; UK/EU SmPC contraindicates CrCl ≤25 mL/min, while US labeling does not require renal dose adjustment but dialysis patients were not studied
- LMWH: anti-Xa monitoring if eGFR <30 and therapeutic dose needed
📄
Trial One-Pager Summaries — Bedside Reference
Collapsible · Click to expand
CAPRIE · COMPASS · VOYAGER · CASPAR · Dutch BOA · CASTLE
CAPRIE · COMPASS · VOYAGER · CASPAR · Dutch BOA · CASTLE
Full citation
CAPRIE Steering Committee. Lancet 1996;348(9038):1329–39
CAPRIE Steering Committee. Lancet 1996;348(9038):1329–39
Design
Multi-centre RCT · N=19,185 · High-risk vascular patients (recent MI, recent ischaemic stroke, or established PAD)
Multi-centre RCT · N=19,185 · High-risk vascular patients (recent MI, recent ischaemic stroke, or established PAD)
Intervention vs Control
Clopidogrel 75 mg OD vs Aspirin 325 mg OD
Clopidogrel 75 mg OD vs Aspirin 325 mg OD
Primary Outcome
Composite: ischaemic stroke, MI, or vascular death
Composite: ischaemic stroke, MI, or vascular death
Overall Result
Clopidogrel: 8.7% RRR vs aspirin (p=0.043) — modest but significant
Clopidogrel: 8.7% RRR vs aspirin (p=0.043) — modest but significant
PAD Subgroup 🔑
23.8% RRR in PAD patients — much larger than in MI or stroke subgroups
23.8% RRR in PAD patients — much larger than in MI or stroke subgroups
Bleeding
GI bleeding lower with clopidogrel; intracranial bleeding similar
GI bleeding lower with clopidogrel; intracranial bleeding similar
Clinical Message
Clopidogrel preferred over aspirin as single antiplatelet in PAD patients
Clopidogrel preferred over aspirin as single antiplatelet in PAD patients
⚡ CLINICAL TAKEAWAY: In PAD specifically, clopidogrel 75 mg OD should be preferred over aspirin as first-line monotherapy. ESVS 2023 Class IIa, ACC/AHA 2024 Class I (either aspirin or clopidogrel, with clopidogrel preferred per PAD subgroup data).
Full citation
Anand SS, Bosch J, Eikelboom JW, et al. Lancet 2018;391(10117):219–29
Anand SS, Bosch J, Eikelboom JW, et al. Lancet 2018;391(10117):219–29
Design
International RCT · N=27,395 stable CAD/PAD patients · 3 arms: Rivaroxaban 2.5 mg BD + ASA vs Rivaroxaban 5 mg BD vs ASA alone
International RCT · N=27,395 stable CAD/PAD patients · 3 arms: Rivaroxaban 2.5 mg BD + ASA vs Rivaroxaban 5 mg BD vs ASA alone
Primary Outcome
CV death, stroke, or MI
CV death, stroke, or MI
PAD Sub-population
~27% of enrolled patients had PAD
~27% of enrolled patients had PAD
MACE Result
21% RRR with Riva 2.5 + ASA vs ASA alone (4.1% vs 5.4%)
21% RRR with Riva 2.5 + ASA vs ASA alone (4.1% vs 5.4%)
MALE Result 🔑
46% RRR MALE (acute limb ischaemia/major amputation) — highly significant
46% RRR MALE (acute limb ischaemia/major amputation) — highly significant
Major Bleeding
3.1% vs 1.9% (ASA) — ↑significant. No ↑fatal or intracranial bleeding
3.1% vs 1.9% (ASA) — ↑significant. No ↑fatal or intracranial bleeding
Stopped early
Trial stopped early for clear efficacy benefit
Trial stopped early for clear efficacy benefit
⚡ CLINICAL TAKEAWAY: DPI (rivaroxaban 2.5 mg BD + aspirin 100 mg) should be considered for stable symptomatic PAD patients with high ischaemic risk and acceptable bleeding risk. The MALE reduction is particularly compelling for vascular surgeons — 46% fewer acute limb events and major amputations.
Full citation
Bonaca MP, Bauersachs RM, et al. N Engl J Med 2020;382(21):1994–2004
Bonaca MP, Bauersachs RM, et al. N Engl J Med 2020;382(21):1994–2004
Design
RCT · N=6,564 · PAD patients undergoing revascularisation (75% EVT, 25% open surgery) · Randomised within 10 days of procedure
RCT · N=6,564 · PAD patients undergoing revascularisation (75% EVT, 25% open surgery) · Randomised within 10 days of procedure
Intervention vs Control
Rivaroxaban 2.5 mg BD + Aspirin 100 mg vs Aspirin alone
Rivaroxaban 2.5 mg BD + Aspirin 100 mg vs Aspirin alone
Primary Outcome
Composite: ALI, major amputation, MI, ischaemic stroke, CV death
Composite: ALI, major amputation, MI, ischaemic stroke, CV death
Primary Result
15% RRR — 17.3% vs 19.9% (HR 0.85, p=0.009)
15% RRR — 17.3% vs 19.9% (HR 0.85, p=0.009)
ALI Reduction 🔑
24% RRR in acute limb ischaemia — most clinically relevant for vascular surgeons
24% RRR in acute limb ischaemia — most clinically relevant for vascular surgeons
TIMI Major Bleeding
2.65% vs 1.87% — significant increase. No ↑fatal or intracranial bleeding
2.65% vs 1.87% — significant increase. No ↑fatal or intracranial bleeding
ISTH Major Bleeding
5.94% vs 4.06% — significant
5.94% vs 4.06% — significant
⚡ CLINICAL TAKEAWAY: Rivaroxaban 2.5 mg BD + aspirin is the preferred post-revascularisation antithrombotic strategy for PAD, particularly post-EVT. It reduces re-hospitalisation for ALI — a complication with very high morbidity and cost. The bleeding risk increase is real but manageable in appropriate patient selection.
Full citation
Belch JJ, Dormandy J, et al. J Vasc Surg 2010;52(4):825–33
Belch JJ, Dormandy J, et al. J Vasc Surg 2010;52(4):825–33
Design
RCT · N=851 · Infrainguinal bypass surgery · Double-blind placebo-controlled
RCT · N=851 · Infrainguinal bypass surgery · Double-blind placebo-controlled
Intervention vs Control
Aspirin + Clopidogrel 75 mg OD vs Aspirin + Placebo
Aspirin + Clopidogrel 75 mg OD vs Aspirin + Placebo
Primary Outcome
Graft occlusion, limb loss, or death
Graft occlusion, limb loss, or death
Overall Result
No significant overall difference between DAPT and single APT (HR 0.98)
No significant overall difference between DAPT and single APT (HR 0.98)
Key Subgroup 🔑
Prosthetic below-knee bypass: DAPT beneficial (HR 0.65, p=0.025). Vein bypass: no benefit from DAPT.
Prosthetic below-knee bypass: DAPT beneficial (HR 0.65, p=0.025). Vein bypass: no benefit from DAPT.
Bleeding
DAPT: higher bleeding rates (not fatal; expected with dual therapy)
DAPT: higher bleeding rates (not fatal; expected with dual therapy)
Limitation
Underpowered for subgroup analyses; mixed graft types and locations
Underpowered for subgroup analyses; mixed graft types and locations
⚡ CLINICAL TAKEAWAY: DAPT post-bypass is only beneficial for prosthetic (synthetic) below-knee bypass grafts. Vein graft recipients should not receive routine DAPT solely because of the bypass. Baseline SAPT is acceptable; DPI or selected VKA may be considered in specific high-risk, low-bleeding-risk situations.
Full citation
Lancet 2000;355(9201):346–51
Lancet 2000;355(9201):346–51
Design
RCT · N=2,690 · Post-infrainguinal bypass surgery · Oral anticoagulants (OAC) vs aspirin 80 mg
RCT · N=2,690 · Post-infrainguinal bypass surgery · Oral anticoagulants (OAC) vs aspirin 80 mg
OAC target
INR 3.0–4.5 (high intensity — note: higher than current practice)
INR 3.0–4.5 (high intensity — note: higher than current practice)
Primary Outcome
Graft occlusion, limb loss, MI, stroke, or death
Graft occlusion, limb loss, MI, stroke, or death
Overall Result
No significant difference in overall composite outcome between OAC and aspirin
No significant difference in overall composite outcome between OAC and aspirin
Key Subgroup 🔑
Vein bypass: trend toward OAC benefit (not significant); prosthetic: ASA numerically better
Vein bypass: trend toward OAC benefit (not significant); prosthetic: ASA numerically better
Bleeding
OAC: significantly more major bleeding events
OAC: significantly more major bleeding events
Limitation
Very high INR target; warfarin not preferred today; no DOAC comparison
Very high INR target; warfarin not preferred today; no DOAC comparison
⚡ CLINICAL TAKEAWAY: Routine oral anticoagulation post-infrainguinal bypass is NOT recommended. Aspirin (or clopidogrel for prosthetic below-knee) is preferred. Oral anticoagulation should be reserved for specific high-risk cases (hypercoagulable state, recurrent graft thrombosis) and individualised per current DOAC options.
Full citation
Hiatt WR, Money SR, Brass EP. J Vasc Surg 2008;47(2):330–6
Hiatt WR, Money SR, Brass EP. J Vasc Surg 2008;47(2):330–6
Design
Prospective observational safety study · N=1,435 · PAD patients on cilostazol 100 mg BD × ≥3 years
Prospective observational safety study · N=1,435 · PAD patients on cilostazol 100 mg BD × ≥3 years
Purpose
Established long-term safety profile of cilostazol — addressing concerns from related PDE3 inhibitor (milrinone) mortality data in HF
Established long-term safety profile of cilostazol — addressing concerns from related PDE3 inhibitor (milrinone) mortality data in HF
Key Result
No increased cardiac mortality in non-HF PAD patients. Safe long-term in appropriately selected patients.
No increased cardiac mortality in non-HF PAD patients. Safe long-term in appropriately selected patients.
Common Side Effects
Headache (34%), diarrhoea (19%), palpitations (13%) — most resolve with time or dose reduction
Headache (34%), diarrhoea (19%), palpitations (13%) — most resolve with time or dose reduction
Discontinuation rate
~25% at 3 years due to side effects — counsel patients early
~25% at 3 years due to side effects — counsel patients early
HF patients
Excluded from CASTLE — HF remains absolute CI
Excluded from CASTLE — HF remains absolute CI
⚡ CLINICAL TAKEAWAY: Cilostazol is safe for long-term use in PAD patients without HF. The 25% discontinuation rate underlines the importance of patient counselling about side effects — particularly headache in the first 2 weeks. Screening for HF before prescribing is mandatory.
Full citation
Megaly M, Abraham B, Saad M, et al. Vasc Med 2019;24(4):313–23
Megaly M, Abraham B, Saad M, et al. Vasc Med 2019;24(4):313–23
Design
Systematic review and meta-analysis of RCTs and observational studies examining cilostazol use post-endovascular therapy for PAD
Systematic review and meta-analysis of RCTs and observational studies examining cilostazol use post-endovascular therapy for PAD
Comparisons
Cilostazol + background APT vs background APT alone post-EVT
Cilostazol + background APT vs background APT alone post-EVT
Primary Patency
Significantly improved with cilostazol (OR 1.54, p < 0.001)
Significantly improved with cilostazol (OR 1.54, p < 0.001)
TLR (re-intervention)
Significantly reduced with cilostazol
Significantly reduced with cilostazol
Limb Salvage
No significant difference
No significant difference
Bleeding
No significant increase in major bleeding events
No significant increase in major bleeding events
⚡ CLINICAL TAKEAWAY: Adding cilostazol to background antiplatelet therapy after endovascular intervention improves primary patency and reduces the need for re-intervention. Particularly relevant for below-knee EVT with high restenosis risk. Reassuring safety profile with no significant bleeding excess.
Full citation
Nana P, Spanos K, Tsilimparis N, et al. Eur J Vasc Endovasc Surg 2025;69(2):272–281
Nana P, Spanos K, Tsilimparis N, et al. Eur J Vasc Endovasc Surg 2025;69(2):272–281
Design
Multi-centre observational study · F/B-EVAR patients (fenestrated or branched endovascular aortic repair) for complex aortic aneurysms
Multi-centre observational study · F/B-EVAR patients (fenestrated or branched endovascular aortic repair) for complex aortic aneurysms
Question
Does antiplatelet regimen (single APT vs DAPT) affect target vessel patency and outcomes post-F/B-EVAR?
Does antiplatelet regimen (single APT vs DAPT) affect target vessel patency and outcomes post-F/B-EVAR?
Key Finding
DAPT associated with better target vessel patency — particularly for renal and visceral stented vessels
DAPT associated with better target vessel patency — particularly for renal and visceral stented vessels
Recommendation
DAPT for 3–6 months may be considered in selected low-bleeding-risk patients, then single APT lifelong
DAPT for 3–6 months may be considered in selected low-bleeding-risk patients, then single APT lifelong
Limitation
Observational; selection bias; variable F/B-EVAR configurations
Observational; selection bias; variable F/B-EVAR configurations
⚡ CLINICAL TAKEAWAY: After complex aortic endovascular repair with fenestrated or branched stent-grafts, early DAPT (aspirin + clopidogrel) for 3–6 months may be considered to protect multiple stented visceral/renal vessels, but evidence is observational and patient bleeding risk must drive the decision. Thereafter, single APT lifelong.
⚡
Quick-Reference Decision Summary
Bedside one-glance reference
Antiplatelet & Anticoagulation Regimen by Clinical Scenario — At a Glance
| Scenario | Regimen | Duration | Add PPI? |
|---|---|---|---|
| Stable PAD / IC (no revascularisation) | Single APT Clopidogrel 75 mg preferred | Lifelong | If GI risk |
| IC + walking-distance symptoms | Single APT + Cilostazol 100 mg BD | Ongoing (review 3-monthly) | Yes |
| High-risk stable PAD (COMPASS eligible) | DPI Rivaroxaban 2.5 mg BD + ASA 100 mg | Lifelong | Yes |
| Post-EVT (iliac/fem-pop, simple) | Single APT or short DAPT | If DAPT used: usually ~1 month → single APT | If DAPT / GI risk |
| Post-EVT (below-knee, complex/DES) | DAPT ASA + Clop for a defined short course and/or DPI Riva 2.5 + ASA if eligible | 1–3 months DAPT; DPI long-term if suitable | Yes if DAPT / GI risk |
| Post-EVT, high MALE risk (VOYAGER eligible) | DPI Rivaroxaban 2.5 mg BD + ASA 100 mg | Long-term | Yes |
| Post-vein bypass (any level) | Single APT baseline; consider DPI or selected VKA in high-risk grafts | Lifelong antithrombotic plan individualized | If GI risk |
| Post-prosthetic below-knee bypass | DAPT ASA + Clopidogrel | 3–6 months → single APT | Yes |
| Post-EVAR (standard) | Single APT ASA or Clopidogrel | Lifelong | If GI risk |
| Post-F/B-EVAR (complex AAA) | DAPT ASA + Clopidogrel may be considered | 3–6 months in selected patients → single APT | Yes |
| PAD + AF (stable, post-revascularisation) | DOAC + ASA (short-term) → DOAC alone | 1–6 months dual, then DOAC mono | Yes |
| PAD + AF + recent EVT (<1 month) | DOAC + single APT preferred; triple only if unavoidable and very short | Step down rapidly to DOAC alone or DOAC + single APT | Mandatory |
| Cilostazol addition to DAPT (triple APT) | DAPT + Cilostazol 100 mg BD, timed away from meals | 1–3 months then review | Mandatory if GI risk |
📚
Structured References
Guidelines · Trials · Disease-specific evidence
How to Read the Reference List
The references are grouped by clinical purpose rather than alphabetically. This makes the evidence easier to use at the bedside: first the major guidelines, then the pivotal trials, then disease-specific supporting literature for cilostazol, AVF, aneurysm disease, perioperative management, and mechanistic evidence.
| Reference | Why It Matters in This Article |
|---|---|
| Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease. J Am Coll Cardiol. 2024. | Core contemporary PAD recommendations: SAPT, DAPT after revascularisation, and rivaroxaban 2.5 mg twice daily plus aspirin. |
| Twine CP, Kakkos SK, Aboyans V, et al. Editor’s Choice — European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases. Eur J Vasc Endovasc Surg. 2023;65(5):627–689. | Main European antithrombotic framework for PAD, bypass, endovascular intervention, AVF, and patients already requiring anticoagulation. |
| Nordanstig J, Behrendt CA, Baumgartner I, et al. European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication. Eur J Vasc Endovasc Surg. 2024;68(1):6–105. | Used for asymptomatic PAD, intermittent claudication, exercise therapy, cilostazol positioning, and best medical therapy. |
| Wanhainen A, Van Herzeele I, Bastos Goncalves F, et al. European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms. Eur J Vasc Endovasc Surg. 2024;67(2):192–331. | Used for AAA risk-factor management, antiplatelets in aneurysm patients, EVAR, and complex F/B-EVAR antiplatelet considerations. |
| Naylor R, Rantner B, Ancetti S, et al. European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. Eur J Vasc Endovasc Surg. 2023;65(1):7–111. | Background reference for carotid-related perioperative antiplatelet decision-making and thrombotic-risk context. |
| Trial / Study | Full Citation | Clinical Use |
|---|---|---|
| CAPRIE | CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet. 1996;348(9038):1329–1339. | Supports clopidogrel as a strong SAPT option in symptomatic PAD, with PAD subgroup benefit compared with aspirin. |
| COMPASS PAD Analysis | Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219–229. | Foundation for dual-pathway inhibition in stable symptomatic PAD when bleeding risk is acceptable. |
| VOYAGER PAD | Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382(21):1994–2004. | Main post-revascularisation evidence for rivaroxaban 2.5 mg twice daily plus aspirin to reduce MACE and MALE. |
| CASPAR | Belch JJ, Dormandy J, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease trial. J Vasc Surg. 2010;52(4):825–833. | Clarifies that routine DAPT after bypass is not universally beneficial, with signal mainly in prosthetic graft subgroups. |
| Dutch BOA | Dutch Bypass Oral Anticoagulants or Aspirin Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery: a randomised trial. Lancet. 2000;355(9201):346–351. | Supports conduit-specific thinking: selected vein graft anticoagulation vs aspirin in prosthetic grafts, balanced against bleeding risk. |
| Reference | Clinical Use |
|---|---|
| Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study. J Vasc Surg. 2008;47(2):330–336. | Long-term safety reference for cilostazol in PAD patients without heart failure. |
| Megaly M, Abraham B, Saad M, et al. Outcomes with cilostazol after endovascular therapy of peripheral artery disease. Vasc Med. 2019;24(4):313–323. | Supports cilostazol as an anti-restenosis adjunct after selected peripheral endovascular therapy. |
| Toyoda K, et al. Cilostazol-based combination antiplatelet therapy and bleeding outcomes. 2014. | Background evidence for the concept that cilostazol-containing combinations may behave differently from conventional DAPT, though PAD-specific extrapolation should be cautious. |
| Chang et al. Cilostazol and restenosis / repeat angioplasty outcomes after peripheral intervention. 2025. | Emerging supportive evidence; should be interpreted alongside earlier meta-analyses and guideline caution. |
| Topic | Reference | Clinical Use |
|---|---|---|
| AVF / dialysis access | Dember LM, et al. Clopidogrel and early arteriovenous fistula thrombosis after fistula creation. JAMA. 2008. | Clopidogrel reduces early AVF thrombosis but does not reliably solve fistula maturation or usability. |
| AAA growth and outcomes | Erdem Yaman A, Poyraz E. Antiplatelet or anticoagulant therapy for abdominal aortic aneurysms: growth and clinical outcomes. Anatol J Cardiol. 2024;28(4):187–193. | Observational aneurysm-growth/outcome signal; not sufficient to prescribe antiplatelets solely as aneurysm-growth therapy. |
| AAA antiplatelet meta-analysis | Systematic review and meta-analysis of antiplatelet therapy in abdominal aortic aneurysm growth and aneurysm-related outcomes. 2023. | Supports cautious wording: antiplatelets are for cardiovascular risk reduction, not proven rupture-prevention therapy. |
| Complex aneurysm / F/B-EVAR | Nana P, Spanos K, Tsilimparis N, et al. Role of antiplatelet therapy in patients managed for complex aortic aneurysms using fenestrated or branched endovascular repair. Eur J Vasc Endovasc Surg. 2025;69(2):272–281. | Supports selected early DAPT after F/B-EVAR to protect renal/visceral target-vessel patency; observational evidence, not blanket rule. |
| Reference | Clinical Use |
|---|---|
| Douketis JD, et al. Perioperative management of antithrombotic therapy: CHEST clinical practice guideline. Chest. 2022. | Supports perioperative interruption and restart principles for antiplatelets and anticoagulants. |
| ASRA / ESRA guidance on regional anesthesia in patients receiving antithrombotic or thrombolytic therapy. | Used for neuraxial timing, especially clopidogrel, cilostazol, LMWH, and low-dose vs therapeutic-dose DOAC separation. |
| Gurbel PA, et al. Antiplatelet and anticoagulant combination strategies in atherothrombosis. 2019. | Mechanistic support for combining platelet-pathway and thrombin-pathway inhibition. |
| Jurk K, et al. Rivaroxaban plus aspirin effects on thrombin generation and platelet activation. 2022. | Mechanistic support for dual-pathway inhibition in PAD-type atherothrombosis. |
| Yu et al. Antithrombotic combination therapy and bleeding risk. 2021. | Supports the cautionary message that adding antithrombotic layers increases bleeding risk and should have a clear indication and exit strategy. |
This document is intended as a clinical reference aid. All clinical decisions must be individualised to the patient. Evidence levels and class recommendations are per ESVS 2023/2024 and ACC/AHA 2024 guidelines unless otherwise stated. This document does not replace guideline review, local policy, multidisciplinary judgement, or patient-specific decision-making.